D-0290-2021 Class II Terminated

Recalled by Aurobindo Pharma USA Inc. — East Windsor, NJ

FDA drug recall D-0290-2021 was initiated by Aurobindo Pharma USA Inc. on Jan 20, 2021 and is designated Class II. Reason for recall: Presence of foreign tablets/capsules: Famotidine 20mg and ibuprofen 400mg tablets were found in a lot of famotidine 40mg. The recall status is terminated (terminated Oct 12, 2023). Affected quantity: 1296 bottles.

Recall details

Product Type
Drugs
Report Date
Mar 10, 2021
Initiation Date
Jan 20, 2021
Termination Date
Oct 12, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1296 bottles

Product description

Famotidine Tablets USP 40mg, 1,000-count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Made in India, NDC 65862-860-99

Reason for recall

Presence of foreign tablets/capsules: Famotidine 20mg and ibuprofen 400mg tablets were found in a lot of famotidine 40mg.

Distribution pattern

TX, CA, GA, PA

Code information

Lot #: P2000467, Exp 7/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0290-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0290-2021. Report a data issue: hello@regdatalab.com.